Centre of epidemiological studies on sexually transmitted infections and AIDS of Catalunya (CEEISCAT). Department of Health, Generalitat of Catalunya, Badalona, Spain.
Instituto de Salud Carlos III, Madrid, Spain.
BMJ Open. 2022 Feb 9;12(2):e053237. doi: 10.1136/bmjopen-2021-053237.
SARS-CoV-2 seroprevalence studies are currently being recommended and implemented in many countries. Forming part of the COVID-19 monitoring and evaluation plan of the Catalan Government Health Department, our network aims to initiate a primary healthcare sentinel monitoring system as a surrogate of SARS-CoV-2 exposure in the Barcelona Metropolitan Area.
The seroCAP is a serial cross-sectional study, which will be performed in the Barcelona Metropolitan Area to estimate antibodies against SARS-CoV-2. From February 2021 to March 2022, the detection of serum IgG antibodies against SARS-CoV-2 trimeric spike protein will be performed on a monthly basis in blood samples collected for diverse clinical purposes in three reference hospitals from the three Barcelona healthcare areas (BCN areas). The samples (n=2588/month) will be from patients attended by 30 primary healthcare teams at 30 basic healthcare areas (BHA). A lab software algorithm will systematically select the samples by age and sex. Seroprevalence will be estimated and monitored by age, sex, BCN area and BHA. Descriptive and cluster analysis of the characteristics and distribution of SARS-CoV-2 infections will be performed. Sociodemographic, socioeconomic and morbidity-associated factors will be determined using logistic regression. We will explore the association between seroprevalence, SARS-CoV-2 confirmed cases and the implemented measures using interrupted time series analysis.
Ethical approval was obtained from the University Institute Foundation for Primary Health Care Research Jordi Gol i Gurina ethics committee. An informed consent is not required regarding the approval of the secondary use of biological samples within the framework of the COVID-19 pandemic. A report will be generated quarterly. The final analysis, conclusions and recommendations will be shared with the stakeholders and communicated to the general public. Manuscripts resulting from the network will be submitted for publication in peer-reviewed journals.
目前，许多国家都在推荐和实施 SARS-CoV-2 血清流行率研究。作为加泰罗尼亚政府卫生部 COVID-19 监测和评估计划的一部分，我们的网络旨在启动初级保健监测系统，作为巴塞罗那大都市区 SARS-CoV-2 暴露的替代指标。
seroCAP 是一项血清学横断面研究，将在巴塞罗那大都市区进行，以估计针对 SARS-CoV-2 的抗体。从 2021 年 2 月至 2022 年 3 月，将每月在三家参考医院采集的用于各种临床目的的血液样本中检测针对 SARS-CoV-2 三聚体刺突蛋白的血清 IgG 抗体。这些样本（每月 2588 份）将来自巴塞罗那三个卫生区（BCN 区）的 30 个初级保健团队就诊的患者。实验室软件算法将按年龄和性别系统地选择样本。将按年龄、性别、BCN 区和 BHA 监测和估计血清流行率。将对 SARS-CoV-2 感染的特征和分布进行描述性和聚类分析。使用逻辑回归确定与社会人口学、社会经济和发病相关的因素。我们将使用中断时间序列分析探索血清流行率、SARS-CoV-2 确诊病例和实施措施之间的关联。
该研究已获得大学初级保健研究基金会 Jordi Gol i Gurina 伦理委员会的批准。在 COVID-19 大流行框架内，无需获得关于同意使用生物样本进行二次使用的知情同意。将每季度生成一份报告。最终分析、结论和建议将与利益相关者共享，并向公众传播。网络产生的手稿将提交给同行评审期刊发表。
